Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Selpercatinib in RET-Altered Thyroid Cancers
NCT04759911Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2021
- Primary completion
- Nov 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of selpercatinib in thyroid cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2021; status: active, not recruiting.
02
Drugs
selpercatinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT04759911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04759911.